My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

183.09 -3.12 (-1.68%)

Streaming Delayed Price Updated: 11:32 AM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Buy This Stock Before Everyone Else Does ↗

July 14, 2021

This biotech has significant upside left.

Via The Motley Fool

Ditch Dogecoin: These 3 Stocks Could Double Your Money ↗

June 23, 2021

The path to a twofold or greater return is straightforward for each of these stocks.

Via The Motley Fool

Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022 ↗

June 15, 2021

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14...

Via Benzinga

2 Top Biotech Stocks to Buy for Summer 2021 ↗

June 05, 2021

Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.

Via The Motley Fool

Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript ↗

May 10, 2021

AXSM earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Thinking About Buying Stock In Immunome, Axsome Or Etsy? ↗

April 26, 2021

Immunome Inc (NASDAQ:IMNM) shares are trading higher by 9.25% by $32.28 after the ...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021 ↗

June 10, 2021

Upgrades According to Argus Research, the prior rating for Zoom Video Communications Inc (NASDAQ:ZM) was changed from Hold to Buy. Zoom Video Communications earned $1.32...

Via Benzinga

Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027

May 05, 2021

Via FinancialNewsMedia

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

2 Top Biotech Stocks to Buy Right Now ↗

April 30, 2021

The stocks of Novavax and Axsome Therapeutics are soaring. Here's why.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire-Makers ↗

April 28, 2021

Their stocks have collapsed. But they could still be huge winners.

Via The Motley Fool

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today ↗

April 26, 2021

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR...

Via Benzinga

Why Axsome Therapeutics Stock Is Jumping Today ↗

April 26, 2021

The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.

Via The Motley Fool

38 Stocks Moving In Monday's Mid-Day Session ↗

April 26, 2021

Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug...

Via Benzinga

58 Biggest Movers From Yesterday ↗

April 27, 2021

Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial...

Via Benzinga

FDA Begins Priority Review of Axsome Therapeutics' Potential New Depression Drug ↗

April 26, 2021

The first new treatment for millions of Americans with major depressive disorder could become available this summer.

Via The Motley Fool

Axsome Stock Jumps After Snagging Priority Review For Depression Drug ↗

April 26, 2021

Axsome Therapeutics snagged a speedy review from the FDA for its depression treatment on Monday, leading Axsome stock to gap higher.

Via Investor's Business Daily

AXSM Stock: The Big FDA News Giving Axsome Therapeutics a Boost ↗

April 26, 2021

AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 26, 2021

Gainers Ocugen (NASDAQ:OCGN) shares rose 13.81% to $10.96 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Advaxis...

Via Benzinga

Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder ↗

April 26, 2021

Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD...

Via Benzinga

Alzheimer's Disease: 5 Stocks on Biotech Radars ↗

April 22, 2021

What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other...

Via Talk Markets

Stocks That Hit 52-Week Lows On Wednesday ↗

April 21, 2021

Wednesday morning, 25 companies reached new 52-week lows. Intriguing Points: Lufax Holding (NYSE:LU) was the biggest company by market cap to set a new 52-week low...

Via Benzinga

The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗

April 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 12, 2021

Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (...

Via Benzinga

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue ↗

April 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead ↗

April 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (...

Via Benzinga

The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs ↗

April 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...

Via Benzinga

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug ↗

April 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition